Recently, epigenetic drugs such as DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis) were shown to upregulate CD38 expression, thus augmenting the anti-myeloma effect of daratumumab [18,19,20]. This evidence concerns the gene CD38 and plasma cell myeloma.